Quick orientationEvidence update: 6 October 2026
What is Sermorelin?
Sermorelin has a clinical history as a GHRH analogue, particularly in paediatric/diagnostic contexts. Modern adult wellness claims need separate evidence.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Clinical history includes GH assessment/treatment contexts; modern adult anti-ageing claims are a different question.
What the mechanism suggests
GHRH(1–29) analogue stimulating pituitary GHRH receptors and endogenous GH release.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
GHRH(1–29) analogue stimulating pituitary GHRH receptors and endogenous GH release.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Evidence gap
For this exact compound/use, the page does not pretend that animal, cell, ingredient-level or neighbouring-compound evidence is a human clinical result.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Why there is no big human-results graph here
Evidence-gap noteFor this exact compound and the popular use described on this page, we did not identify a robust controlled human outcome trial suitable for a numerical “before versus after” graph. Rather than manufacture certainty, the page keeps mechanistic/preclinical evidence in its proper lane.
An empty evidence slot is useful information. It tells you where the marketing story is running ahead of the clinical one.
What it doesn't prove: Absence of a highlighted trial is not proof that no study exists; it means no sufficiently robust, directly relevant study was selected for a headline quantitative claim in this edition.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Historical therapeutic context | Growth-hormone-releasing hormone analogue formerly used diagnostically/therapeutically; historical paediatric treatment commonly cited around 0.03 mg/kg SC daily | Long-term, indication-specific | Weight-based | Historical medical use |
| Current status | No current FDA-approved sermorelin product in the US; modern use is largely compounded/off-label | — | — | Regulatory context |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Common clinic start | 200 mcg SC at bedtime | Weeks 1–4 | Starting step | Clinic/community |
| Prime Life standard ladder | 200 mcg weeks 1–4 →300 weeks 5–8 →400 weeks 9–12 →500 weeks 13–16 | 12–16 weeks | 100 mcg increase every 4 weeks | Clinic protocol |
| Prime Life higher ladder | 300→400→500→600 mcg nightly in 4-week blocks | 16 weeks | 100 mcg every 4 weeks | Clinic protocol |
| Common fixed range | 200–500 mcg nightly | 8–16 weeks or longer | Often no formal titration | Community/compounding practice |
Modern 200–600 mcg bedtime schedules are compounded-clinic conventions, not a continuation of a currently licensed US product. Historical weight-based dosing and modern wellness dosing should remain separate.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Endocrine use should be distinguished from wellness marketing.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
An empty evidence slot is useful information. It tells you where the marketing story is running ahead of the clinical one.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.